Ultrapotent chemogenetics for research and potential clinical applications

Area of Science:

• Neuroscience
• Pharmacology
• Biotechnology

Background:

• Chemogenetics allows noninvasive control of cell populations in behaving animals.
• Current chemogenetic systems often lack sufficient potency and selectivity.
• There is a need for chemogenetic tools suitable for both research and human therapeutics.

Purpose of the Study:

• To develop a novel chemogenetic platform for cell activation and silencing.
• To create highly potent and selective chemogenetic agonists.
• To evaluate the utility of this new platform in preclinical models.

Main Methods:

• Development of a new ion channel-based chemogenetic system activated by varenicline.
• Synthesis of subnanomolar-potency agonists (uPSEMs) with high receptor selectivity.
• In vivo characterization in mice and non-human primates using electrophysiology, calcium imaging, PET, and behavioral testing.

Main Results:

• A novel chemogenetic platform controlled by low doses of varenicline was successfully developed.
• Ultrapotent agonists (uPSEMs) with subnanomolar potency and high selectivity were synthesized.
• The platform demonstrated efficacy and safety in preclinical models, including in a rhesus monkey.

Conclusions:

• The developed receptor-ligand system offers a significant advancement in chemogenetics.
• This platform provides a potent, selective, and potentially translatable tool for neuroscience research.
• The findings support the potential for future clinical applications of this chemogenetic technology.